收费全文 | 14552篇 |
免费 | 813篇 |
国内免费 | 235篇 |
耳鼻咽喉 | 131篇 |
儿科学 | 124篇 |
妇产科学 | 213篇 |
基础医学 | 1135篇 |
口腔科学 | 189篇 |
临床医学 | 1200篇 |
内科学 | 2408篇 |
皮肤病学 | 297篇 |
神经病学 | 1292篇 |
特种医学 | 387篇 |
外科学 | 779篇 |
综合类 | 1242篇 |
现状与发展 | 1篇 |
一般理论 | 9篇 |
预防医学 | 3394篇 |
眼科学 | 346篇 |
药学 | 1240篇 |
16篇 | |
中国医学 | 709篇 |
肿瘤学 | 488篇 |
2025年 | 9篇 |
2024年 | 253篇 |
2023年 | 465篇 |
2022年 | 896篇 |
2021年 | 1178篇 |
2020年 | 1211篇 |
2019年 | 1337篇 |
2018年 | 1217篇 |
2017年 | 948篇 |
2016年 | 718篇 |
2015年 | 464篇 |
2014年 | 783篇 |
2013年 | 1498篇 |
2012年 | 1265篇 |
2011年 | 494篇 |
2010年 | 366篇 |
2009年 | 303篇 |
2008年 | 230篇 |
2007年 | 237篇 |
2006年 | 179篇 |
2005年 | 144篇 |
2004年 | 130篇 |
2003年 | 98篇 |
2002年 | 80篇 |
2001年 | 118篇 |
2000年 | 73篇 |
1999年 | 73篇 |
1998年 | 82篇 |
1997年 | 80篇 |
1996年 | 84篇 |
1995年 | 51篇 |
1994年 | 76篇 |
1993年 | 53篇 |
1992年 | 54篇 |
1991年 | 28篇 |
1990年 | 35篇 |
1989年 | 37篇 |
1988年 | 34篇 |
1987年 | 25篇 |
1986年 | 22篇 |
1985年 | 47篇 |
1984年 | 22篇 |
1983年 | 19篇 |
1982年 | 24篇 |
1981年 | 19篇 |
1980年 | 14篇 |
1978年 | 9篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1975年 | 5篇 |
Background
Although it is known that women do not participate in trials as frequently as men, there are limited recent data examining how women recruitment has changed over time.Methods
We conducted MEDLINE search using a validated strategy for randomized trials published in New England Journal of Medicine, Lancet, and Journal of the American Medical Association between 1986 and 2015, and included trials evaluating pharmacologic or nonpharmacologic therapies. We abstracted data on demographics, intervention type, clinical indication, and trial design characteristics, and examined their relationships with women enrollment.Results
In total, 598 trials met inclusion criteria. Women enrollment increased significantly over time (21% between 1986 and 1990 to 33% between 2011 and 2015; Pfor trend < 0.001) and did not differ by journal or funding source. Women enrollment varied with clinical indication, comprising 37% for non–coronary artery disease vascular trials, 30% for coronary artery disease trials, 28% for heart failure trials, and 28% for arrhythmia trials (P < 0.001), which were all significantly lower than the expected proportion in disease populations (P < 0.001). Women enrollment varied with trial type (31%, 29%, and 26% for pharmacologic, device, and procedural trials, respectively; P = 0.001). These findings were corroborated using multivariable analysis. We found significant positive correlations between women enrolled, and mean age and total number of participants. Fewer women were enrolled in trials reporting statistically significant results than those who did not (P = 0.001).Conclusions
Although enrollment of women has increased over time, it remains lower than the relative proportion in the disease population. Future studies should elucidate the reasons for persistent under-representation of women in clinical trials. 相似文献Background
Vitiligo is an autoimmune disease with varying pathological features. Activation of the CCL20-CCR6 axis plays an important role in chronic inflammatory diseases. However, whether CCL20-CCR6 and Th1/17 cells are indicative of active vitiligo is unclear.Objective
To investigate the potential role of CCL20 and the involvement of Th1/17 and Tc1/17 cells in the mechanism in vitiligo.Methods
One hundred patients with vitiligo, and 20 healthy controls were included. The serum and blister fluid IL-17, IFN-γ, CCL20, and CXCL10 were studied using enzyme-linked immunosorbent assays. The numbers of Th1/17 cells and Tc1/17 cells in circulation were quantified using flow cytometry. CCR6 mRNA in peripheral blood mononuclear cells (PBMCs) was analyzed by real-time polymerase chain reaction and the protein level was confirmed by western blotting. CCR6 and CCL20 expression in lesions was analyzed by immunohistochemistry.Results
The serum CCL20 level was significantly elevated in patients with vitiligo. The level of serum CCL20 was higher in active than in the stable stage, which correlated positively with the Vitiligo European Task Force spreading score and the Vitiligo Area Scoring Index score. Patients with active vitiligo had elevated numbers of circulating Th1/17 cells and Tc1/17 cells, and upregulated expression of CCR6 in PBMCs and lesions. After effective treatment, the level of CCL20 in sera and blister fluid was significantly decreased, as were the numbers of circulating Th1/17 cells and Tc1/17 cells.Conclusion
CCL20 might be a vital biomarker of active vitiligo, and circulating Th1/17 and Tc1/17 cells are involved in the pathogenesis of vitiligo. 相似文献Methods: In this study, Wnt4 gene overexpression and knockdown were performed in PINK1 mutant PD transgenic Drosophila, and the protective effect of Wnt4 gene on PD transgenic Drosophila and its possible mechanism were explored. The Wnt4 gene was screened in the previous experiment; And by using the PD transgenic Drosophila model of the MHC-Gal4/UAS system, the PINK1 gene could be specifically activated in the Drosophila muscle tissue.
Results: In PINK1 mutation transgenic fruit flies, the Wnt4 gene to study its implication on PD transgenic fruit flies’ wing normality and flight ability. We found that overexpression of Wnt4 gene significantly reduced abnormality rate of PD transgenic Drosophila and improved its flight ability, and then, increased ATP concentration, enhanced mitochondrial membrane potential and normalized mitochondrial morphology were found. All of these findings suggested Wnt4 gene may have a protective effect on PD transgenic fruit flies. Furthermore, in Wnt4 gene overexpression PD transgenic Drosophila, down-regulation autophagy and apoptosis-related proteins Ref(2)P, Pro-Caspase3, and up-regulation of Beclin1, Atg8a, Bcl2 protein were confirmed by Western Blotting.
Conclusion: The results imply that the restoring of mitochondrial function though Wnt4 gene overexpression in the PINK1 mutant transgenic Drosophila may be related to autophagy and/or apoptosis. 相似文献